New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareIGF-1 LR3 vs SS-31 (Elamipretide)

IGF-1 LR3 vs SS-31 (Elamipretide)

Side-by-side comparison of key properties, dosing, and research.

Anabolic & IGF
IGF-1 LR3
Anti-Aging & Longevity
SS-31 (Elamipretide)
Summary
IGF-1 LR3 is a synthetic analog of Insulin-like Growth Factor-1 with an extended half-life. It is one of the most potent anabolic peptides available, directly stimulating muscle cell hyperplasia and hypertrophy, and is the downstream mediator of many of GH's anabolic effects.
SS-31 (Elamipretide) is a synthetic mitochondria-targeting tetrapeptide that concentrates in the inner mitochondrial membrane and protects cardiolipin from oxidative damage. It is one of the most promising mitochondrial longevity compounds, studied in clinical trials for heart failure, renal disease, and age-associated mitochondrial dysfunction.
Half-Life
20–30 hours
~2–5 hours
Admin Route
SubQ, IM
SubQ
Research
Typical Dose
40–80 mcg
5–10 mg
Frequency
Once daily or split twice daily
Daily to several times per week
Key Benefits
  • Direct muscle hypertrophy via IGF-1R stimulation
  • Muscle hyperplasia (new fiber formation) — unique among peptides
  • Rapid gains in lean muscle mass
  • Accelerated recovery from training and injury
  • Increased nutrient uptake by muscle cells
  • Fat oxidation enhancement
  • Bone density improvement
  • Cartilage and connective tissue repair
  • Restores mitochondrial function and ATP production
  • Protects inner mitochondrial membrane cardiolipin
  • Reduces mitochondrial reactive oxygen species (ROS)
  • Improves exercise capacity and reduces fatigue
  • Cardioprotective — studied in heart failure trials
  • Renoprotective — reduces ischemic kidney injury
  • Anti-aging via mitochondrial preservation
  • Potential in neurodegenerative disease prevention
Side Effects
  • Hypoglycemia (significant risk — insulin-like activity)
  • Acromegaly-like effects with excessive long-term use
  • Jaw and hand swelling
  • Organ hypertrophy with extreme doses
  • +2 more
  • Injection site irritation
  • Nausea (rare)
  • Generally well-tolerated in clinical trials
Stacks With